Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company focused on novel therapies for serious rare and ultra-rare genetic diseases. The RARE news feed highlights company announcements on commercial performance, clinical development, and key corporate decisions that shape its rare disease portfolio.
Investors and followers of Ultragenyx can find updates on revenue trends from its approved products Crysvita, Dojolvi, Mepsevii, and Evkeeza in select territories, as well as guidance ranges and commentary on operating expenses and cash position. Earnings-related press releases and Form 8-K summaries detail product sales, royalty revenue, and royalty financing transactions, including agreements involving future Crysvita royalties with OMERS.
The news stream also covers Ultragenyx’s late-stage pipeline and regulatory milestones. Readers can track progress of AAV gene therapy programs such as DTX401 for glycogen storage disease type Ia, UX111 for Sanfilippo syndrome type A, and UX701 for Wilson disease, along with monoclonal antibody UX143 for osteogenesis imperfecta and antisense oligonucleotide GTX-102 for Angelman syndrome. Company releases describe Phase 3 study results, longer-term follow-up data, regulatory designations, rolling BLA submissions, and responses to FDA communications such as Complete Response Letters.
In addition, the RARE news page features items on conference presentations, investor events, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). By reviewing these updates, users can follow how Ultragenyx manages its commercial portfolio, advances its clinical pipeline, and executes financing and collaboration strategies in the rare and ultra-rare disease space.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has approved stock options and restricted stock units for a newly hired non-executive officer. The grant, dated November 16, 2022, includes 5,380 stock options and 5,000 restricted stock units. The stock options have a ten-year term with an exercise price of $35.22. Both the stock options and restricted stock units vest over four years, contingent on continuous employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company’s commitment to attracting talent in the biopharmaceutical sector focused on rare diseases.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CFO Mardi Dier will leave the company on November 15, 2022, for a new role at ACELYRIN, INC. Ted Huizenga and Aaron Olsen will manage finance activities during the search for Dier's successor. CEO Emil Kakkis praised Dier's contributions over her two-plus years at Ultragenyx, highlighting the company's fiscal responsibility heading into 2023. Ultragenyx focuses on developing novel therapies for rare genetic diseases, aiming to provide safe and effective treatments.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences. The events include the Stifel Healthcare Conference on November 15, 2022, at 1:50 PM EST in New York and the Jefferies London Healthcare Conference on November 17, 2022, at 10:25 AM GMT. Live and archived webcasts will be available on the company's website for 90 days. Ultragenyx is dedicated to developing novel therapies for serious rare diseases, focusing on unmet medical needs with its diverse portfolio of approved treatments.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported third-quarter 2022 total revenue of $90.7 million, including $64.5 million from Crysvita. The company reaffirms its 2022 revenue guidance for Crysvita between $250 million and $260 million, and Dojolvi between $55 million and $65 million. Operating expenses reached $315.8 million, leading to a net loss of $245.1 million or $3.50 per share. Key clinical milestones include completion of enrollment for several pivotal trials expected by year-end.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on November 2, 2022, at 5:00 PM ET to discuss Q3 2022 financial results and corporate updates. This call will provide insights into the company's performance and strategic direction as it focuses on developing therapies for rare genetic diseases. The live webcast will be accessible via the company's website, along with a replay available for a year. Ultragenyx aims to deliver effective therapies promptly, addressing significant unmet medical needs in the rare disease space.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options totaling 13,000 shares and 6,500 restricted stock units to a newly hired non-executive officer. Approved by the compensation committee, these awards are part of the Employment Inducement Plan under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $41.41 per share. The stock options and restricted stock units vest over four years, contingent on continuous employment.
On September 9, 2022, Ultragenyx Pharmaceutical (NASDAQ: RARE) and Mereo BioPharma (NASDAQ: MREO) announced the presentation of new data from Mereo's Phase 2b ASTEROID study and details of the Phase 2/3 Orbit study at the ASBMR Annual Meeting in Austin, Texas, running from September 9-12, 2022. Setrusumab, a monoclonal antibody for Osteogenesis Imperfecta (OI), will be discussed, highlighting its significance for the 60,000 OI patients in the US and Europe. Key presentations include results from the ASTEROID study and insights from the IMPACT Survey.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, Chief Medical Officer of Gene Therapy, will join a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on September 7, 2022, at 11:20 AM ET. This panel discussion highlights the company’s commitment to addressing serious rare and ultra-rare genetic diseases. Participants can access the live and archived webcast on Ultragenyx's website, available for 90 days post-event. Ultragenyx focuses on developing innovative therapies for high unmet medical needs in rare diseases.
On August 17, 2022, Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the granting of stock options and restricted stock units to two new non-executive officers. A total of 19,020 stock options and 12,910 restricted stock units were awarded under the Ultragenyx Employment Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $49.31, matching the closing price on the grant date. The vesting schedule includes a four-year period with certain conditions based on continued employment.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of non-qualified stock options for 27,500 shares and 14,500 restricted stock units to two newly hired non-executive officers. This award follows the Ultragenyx Employment Inducement Plan and was approved by the compensation committee on August 1, 2022. The stock options have a ten-year term with an exercise price of $50.63 per share. The restricted stock units vest over four years, promoting employee retention and aligning interests with shareholders.